I. Möller

发表

Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival

D. Schadendorf, P. Jansen, S. Ugurel, 2022, Cancers.

Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphology.

D. Schadendorf, P. Jansen, E. Livingstone, 2021, European journal of cancer.

Clinical and genetic analysis of melanomas arising in acral sites.

D. Schadendorf, P. Jansen, T. Brinker, 2019, European journal of cancer.

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi

J. Klode, D. Schadendorf, P. Jansen, 2019, Cancers.

Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors.

D. Schadendorf, R. Scolyer, T. Pietsch, 2017, The Journal of investigative dermatology.

Diagnosing a Primary Leptomeningeal Melanoma by Gene Mutation Signature.

D. Schadendorf, R. Murali, A. Sucker, 2016, The Journal of investigative dermatology.

Oncogene status as a diagnostic tool in ocular and cutaneous melanoma.

D. Schadendorf, B. Schilling, C. Franklin, 2016, European journal of cancer.

TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.

D. Schadendorf, B. Schilling, J. Malvehy, 2014, Journal of the National Cancer Institute.

Analysis of SDHD promoter mutations in various types of melanoma

D. Schadendorf, B. Schilling, W. Sondermann, 2015, Oncotarget.

Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions

D. Schadendorf, P. Jansen, S. Ugurel, 2022, Cancers.

Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors

D. Schadendorf, P. Jansen, A. Bankfalvi, 2022, International journal of cancer.

TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.

M. Weichenthal, J. Utikal, D. Schadendorf, 2021, European journal of cancer.

Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi

D. Schadendorf, B. Schilling, R. Scolyer, 2017, Modern Pathology.

Clinical and pathological characteristics of familial melanoma with germline TERT promoter variants

D. Schadendorf, P. Jansen, E. Livingstone, 2022, Pigment cell & melanoma research.

Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.

D. Schadendorf, B. Schilling, H. Reis, 2017, Investigative ophthalmology & visual science.

NF1 mutations in conjunctival melanoma

D. Schadendorf, B. Schilling, C. Franklin, 2018, British Journal of Cancer.

Genetic characterization of advanced conjunctival melanoma and response to systemic treatment.

D. Schadendorf, P. Jansen, K. Kähler, 2022, European journal of cancer.

SF3B1 and BAP1 mutations in blue nevus-like melanoma

D. Schadendorf, B. Schilling, R. Scolyer, 2017, Modern Pathology.

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?

D. Schadendorf, A. Sucker, K. Griewank, 2015, Journal of Translational Medicine.

GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors

D. Schadendorf, P. Jansen, M. Gunzer, 2021, Frontiers in Genetics.

Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles

D. Schadendorf, C. Franklin, R. Murali, 2018, Modern Pathology.

NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.

M. Weichenthal, J. Utikal, D. Schadendorf, 2021, European journal of cancer.

Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling

D. Schadendorf, D. Schrimpf, A. von Deimling, 2018, Clinical Cancer Research.

Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system

D. Schadendorf, B. Schilling, R. Scolyer, 2016, Journal of Neuro-Oncology.

Frequent TERT Promoter Mutations in Ocular Surface Squamous Neoplasia.

D. Schadendorf, B. Schilling, D. Meller, 2015, Investigative ophthalmology & visual science.

TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma

D. Schadendorf, B. Schilling, R. Murali, 2013, PloS one.

Rare TERT Promoter Mutations Present in Benign and Malignant Cutaneous Vascular Tumors

D. Schadendorf, P. Jansen, A. Sucker, 2021, Dermato.

Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway

Donavan T. Cheng, D. Schadendorf, B. Schilling, 2015, Oncotarget.

NF1 mutations in conjunctival melanoma

D. Schadendorf, B. Schilling, C. Franklin, 2018, British Journal of Cancer.

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi

J. Klode, D. Schadendorf, P. Jansen, 2019, Cancers.